SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Recruiting · NCT06389097 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.
Who can take part
Inclusion criteria
- Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223
- Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617
- \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol
- Age \> 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Histologic confirmation of malignancy
Exclusion criteria
- Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol.
- Patient unable to tolerate SPECT scan time, scan frequency, or position.
Where it is running
1 location listed across 1 US state.
- Johns Hopkins University - Baltimore, Maryland, United States